Castration-Resistant Prostate Cancer (CRPC) Treatment Market Strategies and Forecasts, 2023 to 2033
According to Future Market Insights, the Castration-Resistant Prostate Cancer (CRPC) Treatment Market is anticipated to expand at a rate of 9.5% CAGR from 2023 to 2033. Castration-Resistant Prostate Cancer (CRPC) Treatment is anticipated to reach a market worth of US$28 billion by the year 2033.
Growth of the market can be attributed to the increasing prevalence of
CRPC, coupled with the growing awareness and diagnosis of the disease, is one
of the key drivers of this growth. In addition, the market is being driven by
the introduction of novel treatments that offer better efficacy and fewer side
effects than traditional therapies.
Request Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16739
Another important factor driving the growth of the CRPC treatment market
is the increasing use of combination therapies. By using a combination of
different drugs and treatments, physicians can better target the cancer and
improve treatment outcomes. For example, combining targeted therapies with
immunotherapies has shown promise in early studies.
One of the most promising developments in CRPC treatment is the use of
targeted therapies. These drugs are designed to specifically target the cancer
cells and limit their growth and spread, while minimizing damage to healthy
cells. Targeted therapies such as enzalutamide and abiraterone have shown
significant benefits in treating CRPC, leading to their approval by regulatory
agencies around the world.
Key Takeaways from the Market Study
- Castration-Resistant
Prostate Cancer (CRPC) Treatment market expected to grow at a value of
9.5% CAGR during the forecast period 2023-2033.
- By drug
delivery method, oral route is expected to possess 55% market share for
castration-resistant prostate cancer (CRPC) treatment market in 2023.
- North America
is expected to possess 46% market share for castration-resistant prostate
cancer (CRPC) treatment market in 2023.
- Europe is
expected to possess 40% market share for castration-resistant prostate
cancer (CRPC) treatment market in 2023.
“The development of new targeted therapies, immunotherapies, and
combination therapies is driving this growth, and there is significant
potential for continued innovation in the years to come.” states an FMI
analyst
Competitive Landscape
Key players in the castration-resistant prostate cancer (CRPC) treatment
market are Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott
Laboratories, GlaxoSmithKline PLC, Northwest Biotherapeutics, Inc., Active
Biotech AB, Astellas Pharma, Inc, Dendreon Corporation
- Sanofi, a key
player in CRPC treatment market is involved in the development of other
drugs for the treatment of cancer more broadly, including immunotherapies
and targeted therapies.
- in 2019, Abbott
announced the launch of a new clinical trial to investigate the use of
their drug, ABT-199, in combination with enzalutamide (Xtandi) for the
treatment of metastatic CRPC. ABT-199 is a targeted therapy that works by
inhibiting a protein called BCL-2, which is overexpressed in many cancer
cells.
To learn more about this report @ https://www.futuremarketinsights.com/reports/castration-resistant-prostate-cancer-treatment-market
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased
analysis of the global Castration-Resistant Prostate Cancer (CRPC) Treatment
market, presenting historical analysis from 2018 to 2022 and forecast
statistics for the period of 2023 to 2033.
The study reveals essential insights on the basis of Therapy Type
(Hormonal therapy, Chemotherapy, Immunotherapy, Radiotherapy) Drug Class
(Antineoplastic, Non-steroidal Antiandrogen, Corticosteroids, Microtubule
Inhibitor) Drug Delivery Method (Oral Route, Injectable Route) Distribution Channel
(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Region (North
America, Latin America, Europe, South Asia, East Asia, Oceania, MEA)
Comments
Post a Comment